2.13
전일 마감가:
$2.01
열려 있는:
$2.0291
하루 거래량:
342.25K
Relative Volume:
0.64
시가총액:
$191.72M
수익:
$7.05M
순이익/손실:
$-30.43M
주가수익비율:
-5.623
EPS:
-0.3788
순현금흐름:
$21.84M
1주 성능:
-1.39%
1개월 성능:
+19.66%
6개월 성능:
-22.26%
1년 성능:
+29.48%
Proqr Therapeutics N V Stock (PRQR) Company Profile
PRQR을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
PRQR
Proqr Therapeutics N V
|
2.13 | 191.72M | 7.05M | -30.43M | 21.84M | -0.3788 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-29 | 재개 | Cantor Fitzgerald | Overweight |
2025-04-29 | 개시 | Evercore ISI | Outperform |
2025-03-10 | 업그레이드 | Citigroup | Neutral → Buy |
2025-01-10 | 개시 | Oppenheimer | Outperform |
2024-10-29 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2023-11-08 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
2023-03-30 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
2022-12-22 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
2022-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
2022-02-11 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
2022-02-11 | 다운그레이드 | Stifel | Buy → Hold |
2022-02-01 | 개시 | Raymond James | Strong Buy |
2021-05-03 | 개시 | Stifel | Buy |
2021-03-25 | 재확인 | Citigroup | Buy |
2020-11-03 | 재개 | Cantor Fitzgerald | Overweight |
2019-03-12 | 재확인 | Chardan Capital Markets | Buy |
2018-12-19 | 개시 | RBC Capital Mkts | Outperform |
2018-11-15 | 개시 | Citigroup | Buy |
2018-09-19 | 개시 | Evercore ISI | Outperform |
2017-09-26 | 재확인 | JMP Securities | Mkt Outperform |
2016-06-20 | 개시 | Chardan Capital Markets | Neutral |
2014-10-15 | 개시 | Deutsche Bank | Buy |
2014-10-13 | 개시 | H.C. Wainwright | Buy |
모두보기
Proqr Therapeutics N V 주식(PRQR)의 최신 뉴스
Bank of America Corp DE Boosts Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected - simplywall.st
Equities Analysts Offer Predictions for PRQR FY2026 Earnings - MarketBeat
Research Analysts Set Expectations for PRQR FY2026 Earnings - Defense World
Jane Street Group LLC Buys Shares of 11,400 ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Analysts Set ProQR Therapeutics (NASDAQ:PRQR) Target Price at $8.00 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Shares Sold by Two Sigma Advisers LP - Defense World
Two Sigma Investments LP Has $1.02 Million Stake in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
Squarepoint Ops LLC Grows Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Two Sigma Investments LP Buys 320,614 Shares of ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of “Buy” by Analysts - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Sees Significant Increase in Short Interest - MarketBeat
ProQR Shareholders Approve Key Resolutions at Annual Meeting - TipRanks
ProQR Therapeutics (NASDAQ:PRQR) Shares Purchased by Northern Trust Corp - MarketBeat
Millennium Management LLC Grows Stock Position in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
BNP Paribas Financial Markets Buys 15,900 Shares of ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Northern Trust Corp Has $1.11 Million Stock Holdings in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Woodline Partners LP Invests $9.43 Million in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
Here's Why ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO May Deserve A Raise - simplywall.st
Millennium Management LLC Buys 2,683,351 Shares of ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Point72 Asset Management L.P. Buys New Position in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year - Investing.com Canada
Cantor Fitzgerald Issues Negative Forecast for PRQR Earnings - MarketBeat
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes Position in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Oppenheimer Has Lowered Expectations for ProQR Therapeutics (NASDAQ:PRQR) Stock Price - Defense World
Research Analysts Issue Forecasts for PRQR FY2025 Earnings - Defense World
ProQR (PRQR) Price Target Cut by Oppenheimer Amid Clinical Updates | PRQR Stock News - GuruFocus
DAFNA Capital Management LLC Buys 661,979 Shares of ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | - GuruFocus
Oppenheimer Adjusts ProQR Therapeutics N.V Price Target to $9 From $15, Maintains Outperform Rating - marketscreener.com
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences - GlobeNewswire
Raymond James Financial Inc. Invests $260,000 in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of “Buy” from Analysts - Defense World
ProQR: Q1 Earnings Snapshot - News-Times
1,181,413 Shares in ProQR Therapeutics (NASDAQ:PRQR) Acquired by ArrowMark Colorado Holdings LLC - MarketBeat
New Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR) - simplywall.st
ProQR Therapeutics NV earnings missed, revenue topped estimates - Investing.com Australia
ProQR Therapeutics NV earnings missed, revenue topped estimates By Investing.com - Investing.com Nigeria
ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Proqr Therapeutics N V (PRQR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):